SARS-CoV-2 spike antibody and longterm T cell responses in MS patients on Fingolimod and Ocrelizumab following SARS-CoV-2 mRNA vaccine

Authors
Category Primary study
Conference40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS 2024
Year 2024
This article has no abstract
Epistemonikos ID: 79a446c1df6379ae9fdfd73e1bcfb3172037e110
First added on: Mar 31, 2026